A brand new class of epilepsy medicines primarily based on an ingredient derived from marijuana might be accessible as quickly as within the second half of 2018 within the United States pending Food and Drug Administration approval.
Officials from GW Pharmaceuticals, the corporate that developed the drug, on Wednesday introduced promising outcomes from a research on 171 sufferers randomized into remedy and placebo teams.
Members of the group, who have been 2 to 55 years of age, have a situation known as Lennox-Gastaut Syndrome and have been affected by seizures that weren’t being managed by current medication.
Click here to read the complete article
MagNerd.com via 420Intel.com ~